Delta133P53Beta and Delta133P53Gamma isoforms are biomarkers of cancer stem cells
US12227767B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 3, 2021 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Dec 5, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p53β isoform, Δ133p53γ isoform, or both Δ133p53β and Δ133p53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.